PT1021418E - 2,3-benzodiazepin-4-onas substituidas e o seu uso - Google Patents

2,3-benzodiazepin-4-onas substituidas e o seu uso

Info

Publication number
PT1021418E
PT1021418E PT97916722T PT97916722T PT1021418E PT 1021418 E PT1021418 E PT 1021418E PT 97916722 T PT97916722 T PT 97916722T PT 97916722 T PT97916722 T PT 97916722T PT 1021418 E PT1021418 E PT 1021418E
Authority
PT
Portugal
Prior art keywords
treating
ameliorating
disease
benzodiazepin
ones
Prior art date
Application number
PT97916722T
Other languages
English (en)
Portuguese (pt)
Inventor
Yan Wang
Haiji Xia
Nancy C Lan
George Field
Sui Xiong Cai
Original Assignee
Euro Celtique Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Euro Celtique Sa filed Critical Euro Celtique Sa
Publication of PT1021418E publication Critical patent/PT1021418E/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D243/00Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/02Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 2
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D243/00Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/10Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
PT97916722T 1996-03-21 1997-03-21 2,3-benzodiazepin-4-onas substituidas e o seu uso PT1021418E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US1381396P 1996-03-21 1996-03-21

Publications (1)

Publication Number Publication Date
PT1021418E true PT1021418E (pt) 2004-10-29

Family

ID=21761900

Family Applications (1)

Application Number Title Priority Date Filing Date
PT97916722T PT1021418E (pt) 1996-03-21 1997-03-21 2,3-benzodiazepin-4-onas substituidas e o seu uso

Country Status (11)

Country Link
US (1) US5891871A (enExample)
EP (1) EP1021418B1 (enExample)
JP (1) JP2000506890A (enExample)
AT (1) ATE267177T1 (enExample)
AU (1) AU2527097A (enExample)
DE (1) DE69729227T2 (enExample)
DK (1) DK1021418T3 (enExample)
ES (1) ES2217406T3 (enExample)
PT (1) PT1021418E (enExample)
WO (1) WO1997034878A1 (enExample)
ZA (1) ZA972496B (enExample)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19604920A1 (de) * 1996-02-01 1997-08-07 Schering Ag Neue 2,3-Benzodiazepinderivate, deren Herstellung und Verwendung als Arzneimittel
DE19604919A1 (de) 1996-02-01 1997-08-07 Schering Ag Neue 2,3-Benzodiazepinderivate, deren Herstellung und Verwendung als Arzneimittel
US6635632B1 (en) * 1996-12-23 2003-10-21 Athena Neurosciences, Inc. Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds
HU227128B1 (en) * 1999-07-07 2010-07-28 Egyt Gyogyszervegyeszeti Gyar New 2,3-benzodiazepine derivatives
DE10004572A1 (de) * 2000-02-02 2001-08-09 Boehringer Ingelheim Pharma Neue positive allosterische AMPA-Rezeptor Modulatoren (PAARM), Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
KR100904011B1 (ko) 2000-06-12 2009-06-22 에자이 알앤드디 매니지먼트 가부시키가이샤 1,2-디하이드로피리딘 화합물 및 그의 제조 방법
US6432944B1 (en) 2000-07-06 2002-08-13 Bristol-Myers Squibb Company Benzodiazepinone β-amyloid inhibitors: arylacetamidoalanyl derivatives
HU225100B1 (hu) * 2000-12-21 2006-06-28 Egyt Gyogyszervegyeszeti Gyar 2,3-Benzodiazepinszármazékok, ilyen hatóanyagot tartalmazó gyógyászati készítmények és alkalmazásuk
US6649607B2 (en) * 2001-05-18 2003-11-18 Vela Pharmaceuticals, Inc. Compositions and methods for treating or preventing convulsions or seizures
WO2002098865A2 (fr) * 2001-06-07 2002-12-12 Neuro3D Inhibiteurs des phosphodiesterases des nucleotides cycliques, preparation et utilisations de ces inhibiteurs
GB0129260D0 (en) 2001-12-06 2002-01-23 Eisai London Res Lab Ltd Pharmaceutical compositions and their uses
US6864251B2 (en) * 2002-12-03 2005-03-08 Vela Pharmaceuticals, Inc. Treatment of LTB4-mediated inflammatory disorders with optically-pure (R)-2,3-benzodiazepines
MXPA05005893A (es) * 2002-12-03 2006-02-08 Vela Pharmaceuticals Inc Composicion farmaceutica de 1-(3-hidroxi -4-metoxifenil) -4-metil-5 -etil-7, 8-dimetoxi- 5h-2, 3-benzodiazepina y usos de la misma.
US6638928B1 (en) 2002-12-03 2003-10-28 Vela Pharmaceuticals, Inc. Treatment of irritable bowel syndrome and nonulcer dyspepsia with substituted 2,3-benzodiazepines
AU2003293405A1 (en) * 2002-12-03 2004-06-23 Vela Pharmaceuticals, Inc. Pharmaceutical composition of 1-(3,4-dimethoxyphenyl)-4-methyl-5-ethyl-7-methoxy-8-hydroxy-5h-2,3-benzodiazepine and uses thereof
US7022700B2 (en) * 2002-12-03 2006-04-04 Vela Pharmaceuticals, Inc. Method of increasing neutrophil production using optically-pure (R)-2,3-benzodiazepines
WO2004062616A2 (en) 2003-01-13 2004-07-29 Cortex Pharmaceuticals, Inc. Method of treating cognitive decline due to sleep deprivation and stress
US20040152694A1 (en) * 2003-02-04 2004-08-05 Istvan Kurucz Methods and compositions for treating inflammatory disorders of the airways
US20040162284A1 (en) * 2003-02-19 2004-08-19 Harris Herbert W. Method of lowering body temperature with (S) tofisopam
US20040224943A1 (en) * 2003-02-19 2004-11-11 Leventer Steven M. Method of lowering body temperature with (R) - 2,3-benzodiazepines
GB0325175D0 (en) * 2003-10-28 2003-12-03 Novartis Ag Organic compounds
MY148809A (en) 2004-07-06 2013-05-31 Eisai R&D Man Co Ltd Crystals of 1,2-dihydropyridine compound and their production process
JP2007153755A (ja) * 2005-12-01 2007-06-21 Gifu Univ プロリン類縁体
EP2338492A1 (en) 2009-12-24 2011-06-29 Universidad del Pais Vasco Methods and compositions for the treatment of alzheimer
FR2972454B1 (fr) * 2011-03-08 2013-03-01 Servier Lab Nouveaux derives dihydro-oxazolobenzodiazepinones, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
WO2014026997A1 (de) 2012-08-16 2014-02-20 Bayer Pharma Aktiengesellschaft 2,3-benzodiazepine
CA2901352A1 (en) 2013-02-19 2014-08-28 Bayer Pharma Aktiengesellschaft Bicyclo 2,3-benzodiazepines and spirocyclically substituted 2,3-benzodiazepines
EP2958922A1 (de) 2013-02-22 2015-12-30 Bayer Pharma Aktiengesellschaft Pyrrolo- und pyrazolo-triazolodiazepine als bet-proteininhibitoren zur behandlung von hyper-proliferativen erkrankungen
US20150376196A1 (en) 2013-02-22 2015-12-31 Bayer Pharma Aktiengesellschaft 4-substituted pyrrolo- and pyrazolo-diazepines
JP2016521755A (ja) 2013-06-13 2016-07-25 ヴェロサイエンス,リミテッド・ライアビリティー・カンパニー 代謝障害を治療するための組成物および方法
CA3122705A1 (en) 2018-12-14 2020-06-18 Eisai R&D Management Co., Ltd. Aqueous based pharmaceutical formulations of 1,2-dihydropyridine compounds

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2085645A1 (en) * 1970-04-22 1971-12-31 Chimidrog 1-phenyl-2,3-benzodiazepin-4-ones - as tranquillizers
HU191698B (en) * 1984-07-27 1987-03-30 Gyogyszerkutato Intezet Process for producing new 1-aryl-5h-2beta-benzodiazepines
HU198494B (en) * 1986-08-15 1989-10-30 Gyogyszerkutato Intezet Process for producing new 3,4-dihydro-5h-2,3-benzodiazepine derivative and acid addition salts thereof, as well as pharmaceutical compositions comprising same
HU219778B (hu) * 1990-12-21 2001-07-30 Gyógyszerkutató Intézet Közös Vállalat Eljárás N-acil-2,3-benzodiazepin-származékok, savaddíciós sóik és az ezeket tartalmazó gyógyászati készítmények előállítására, valamint a vegyületek egy csoportja, és az ezeket tartalmazó gyógyászati készítmények
US5550124A (en) * 1991-12-10 1996-08-27 University Of Southern California Use of peripheral-type benzodiazpine sites for treatment of CNS trauma or disease
US5922773A (en) * 1992-12-04 1999-07-13 The Children's Medical Center Corp. Glaucoma treatment
DE19604920A1 (de) * 1996-02-01 1997-08-07 Schering Ag Neue 2,3-Benzodiazepinderivate, deren Herstellung und Verwendung als Arzneimittel

Also Published As

Publication number Publication date
JP2000506890A (ja) 2000-06-06
DE69729227T2 (de) 2005-05-04
US5891871A (en) 1999-04-06
WO1997034878A1 (en) 1997-09-25
EP1021418B1 (en) 2004-05-19
DK1021418T3 (da) 2004-09-20
DE69729227D1 (de) 2004-06-24
EP1021418A1 (en) 2000-07-26
ZA972496B (en) 1997-10-02
EP1021418A4 (en) 2001-06-13
ES2217406T3 (es) 2004-11-01
AU2527097A (en) 1997-10-10
ATE267177T1 (de) 2004-06-15

Similar Documents

Publication Publication Date Title
PT1021418E (pt) 2,3-benzodiazepin-4-onas substituidas e o seu uso
ATE125701T1 (de) Gabapentin und dessen derivate zur behandlung neurodegenerativer krankheiten.
ATE404201T1 (de) Glycinrezeptorantagonisten und ihre verwendung
FI113651B (fi) Menetelmä terapeuttisesti käyttökelpoisten bentsimidatsoliyhdisteiden valmistamiseksi
BR0205829A (pt) Novas aminas como ligantes dos receptores de histamina-3 e suas aplicações terapêuticas
BR0108547A (pt) Derivados de aminoadamantano como agentes terapêuticos
ES2138983T3 (es) Uso de derivados del acido 2-(n-(2-aminoetil)amino)-acetico para el tratamiento de enfermedades condicionadas por glicosilacion no enzimatica.
ES2137320T3 (es) Derivados de decahidro-isoquinoleina.
PT831799E (pt) Compostos activos ao nivel de um novo sitio de canais calcicos activados por um receptor uteis no tratamento de disturbios neurologicos
MY131442A (en) Excitatory amino acid receptor antagonists
ATE223399T1 (de) Quinazolin-4-on ampa antagonisten
WO1995018616A3 (en) 8-aza, 6-aza and 6,8-diaza-1,4-dihydroquinoxaline-2,3-diones and the use thereof as antagonists for the glycine/nmda receptor
WO2003027068A3 (en) Substituted amines for the treatment of neurological disorders
BR0309486A (pt) Composto ou um seu sal farmaceuticamente aceitável, composição farmacêutica, e, método para o tratamento de uma condição associada com um excesso de taquicininas
WO1996022990A3 (en) Aza and aza (n-oxy) analogs of glycine/nmda receptor antagonists
ES2168456T3 (es) Peptidos que afectan a los linfocitos t.
AR004602A1 (es) Procedimiento para preparar compuestos de acidos 4-amino-2-heterobiciclo [3.1.0]hexan-4,6-dicarboxilicos, de sus sales farmaceuticamente aceptables yenantiomeros de los mismos.
BR9607443A (pt) Composto de 4-aminotetraidrobenzisoxazol ou-isatiazol composição farmacêutica e utilização do composto
GR3036429T3 (en) Bicyclic compounds as excitatory amino acid receptor antagonists.
BR0113974A (pt) Inibidores de aminotransferase dependente de aminoácido de cadeia ramificada e sua utilização no tratamento de doenças neurodegenerativas
ATE216233T1 (de) Indolditerpen alkaloide
DE60209192D1 (de) Inhibitore der Verzweigte-Aminosäure-abhängigen Aminotransferase und deren Verwendung in der Behandlung von Neurodegenerativen Erkrankungen
ATE201993T1 (de) Verwendung von olanzapine zur herstellung eines arzneimittels zur behandlung der zerebralen fokalen ischämie
EA201001895A1 (ru) Пролекарства возбуждающих аминокислот